Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells $36,000.00 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 322,743 shares in the company, valued at approximately $2,904,687. The trade was a 1.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Theravance Biopharma Stock Performance

TBPH stock opened at $9.57 on Friday. The stock’s 50 day simple moving average is $8.36 and its 200 day simple moving average is $8.69. The company has a market cap of $468.16 million, a P/E ratio of -9.48 and a beta of 0.25. Theravance Biopharma, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The firm had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. During the same quarter in the prior year, the firm earned ($0.17) EPS. Equities analysts predict that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TBPH shares. Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Monday, September 16th. TD Cowen cut their price target on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. StockNews.com downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Finally, Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Theravance Biopharma currently has an average rating of “Hold” and a consensus target price of $13.75.

Institutional Trading of Theravance Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in shares of Theravance Biopharma in the third quarter valued at $60,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 3,696 shares during the last quarter. Ballentine Partners LLC bought a new position in Theravance Biopharma in the 3rd quarter valued at about $104,000. Hsbc Holdings PLC bought a new position in Theravance Biopharma in the 2nd quarter valued at about $108,000. Finally, XTX Topco Ltd acquired a new position in Theravance Biopharma during the 2nd quarter valued at about $129,000. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.